Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
Novice learners should complete this path early. It focuses on hygiene, red flags, regulation context, and what to verify before using any compound.
Who it's for: Everyone — especially before first use or when switching suppliers.
Unit 1
Non-negotiable practices for storage, injection, and travel.
You'll be able to
Unit 2
Learn to watch your body and data, not just the scale.
You'll be able to
24 lessons in Safety & Best Practices
7mThe question arrives at the front desk first. Here is a three-tier script that answers it honestly, cites what exists, and never turns into a claim or a referral to a vendor.
9mMost peptide stigma is not a single hazard. It is three different risks that clinics mash together. Separate them and the conversation with counsel, pharmacy, and medical directors gets shorter.
8mIf your team cannot state the regulatory status of each compound in one clean sentence, the menu is not ready. Here is the three-band model clinics use before counsel finishes the memo.
7mVendor PDFs are not primary sources. Here is the order clinics should read FDA and state board pages so status sheets survive the first counsel review.
9mA GLP-1 program is a months-long titration that happens at the patient's kitchen table. This guide covers the operational pieces clinics need: adherence against the titration schedule, side-effect logs the prescriber reads, refill timing, check-in cadence, and the compounded-product issues FDA has flagged.
10mAdding peptides to a med spa is a licensing, sourcing and documentation problem before it is a marketing one. Here is the operational order: prescriber, pharmacy, regulatory status by compound, consent, and a way to track what patients actually do between visits.
9mA warm hour in a carry-on can matter. Learn cold-chain basics for refrigerated peptides, travel logging, and when to talk with your pharmacist or clinician.
9mA certificate of analysis is not a green light for injection. This guide walks through lot linkage, purity specs, and the questions COAs leave unanswered.
9mGLP-1 access is a medical and logistics puzzle. Know when self-directed research should pause and a licensed clinician should lead product choice and monitoring.
9mPhase 3 data on retatrutide side effects, in plain English: how often nausea, diarrhea, dysesthesia (skin burning), low blood pressure and injection-site reactions showed up by dose, and what the trials don't tell you.
7mA favorable advisory vote is not permission to prescribe or compound. Here is the practical standard telehealth clinics should use after the 2026 PCAC meeting.
8mBPC-157 is still a research compound, but the advisory review makes one thing clear: access, sourcing, and evidence quality now matter as much as the mechanism.
7mAmylin agonists can feel GLP-1-like in the gut. Here's how to think about eloralintide tolerability, escalation, and symptom tracking without turning trial data into fear content.
8mMariTide is Amgen's once-monthly obesity candidate. This beginner guide covers the mechanism framing, Phase 2 headlines, and what serious trackers should log.
7mMonthly conjugates can pack a bigger post-dose GI window. Here's how to think about MariTide tolerability using Phase 2 lessons — without fear content.
8mThe regulatory story matters because it changes what you can trust, what you should track, and why supply chain quality now sits beside mechanism in the BPC-157 debate.
10mPet owners are hearing more about BPC-157 and TB-500 for recovery. This guide separates the real biology from the social-media hype and shows what actually matters for healing.
8mThe July 2026 FDA peptide review is important, but it is not an approval event. Here is how to track the meeting, sourcing changes, and protocol decisions without confusing policy movement with clinical proof.
7mEDS changes the safety conversation around peptides. GHK-Cu, BPC-157, and TB-500 are discussed for tissue support, but EDS plus cardiac history should stay clinician-led.
7mMaximize your peptide investment with proper storage techniques that maintain potency and extend shelf life.
8mProtect yourself by learning how to verify peptide quality, understand testing reports, and avoid dangerous products.
7mLearn how to select the perfect insulin syringe for your peptide protocol with our comprehensive guide.
9mLearn about common peptide side effects, how to minimize them, and when they require attention.
7mLearn how to safely travel with your peptides while maintaining proper storage and navigating legal considerations.
Also available at /blog for legacy links.